|
Reuters CV shares fall on FDA concerns over angina drug Monday December 8, 10:00 am ET NEW YORK, Dec 8 (Reuters) - U.S. regulators on Monday expressed concern that an angina drug being developed by CV Therapeutics Inc. (NasdaqNM:CVTX - News) causes an electrical impulse problem that could result in abnormal heart rhythms, sending shares of the company down 16 percent. Concerns voiced by reviewers for the U.S. Food and Drug Administration (News - Websites) were posted on the agency`s Web site on Monday in advance of Tuesday`s meeting of a FDA advisory panel to evaluate whether the medicine, Ranexa, should be approved. ____________________________________________________________ Hat jemand weitere Infos - es geht bei mir nichts über die Ticker! Morgen soll die FDA-Entscheidung über Ranexa kommen. Thanx! Kosto |
|
| aus der Diskussion: | +++ CV Therapeutics Inc (CVTX) - Kurssturz +++ |
| Autor (Datum des Eintrages): | kosto1929 (08.12.03 16:20:19) |
| Beitrag: | 1 von 470 (ID:11549149) |
| Alle Angaben ohne Gewähr © wallstreetONLINE | |